Premium
Efalizumab‐induced autoimmune pancytopenia
Author(s) -
Tom W.L.,
Miller M.D.,
Hurley M.Y.,
Suneja T.,
Kudva G.,
Leonardi C.L.,
Obadiah J.M.
Publication year - 2006
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2006.07437.x
Subject(s) - efalizumab , pancytopenia , medicine , dermatology , immunology , autoimmune disease , psoriasis , plaque psoriasis , antibody , bone marrow
Summary Efalizumab is a recombinant, humanized monoclonal anti‐CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Immune‐mediated thrombocytopenia and anaemia have previously been reported with this therapy. We describe the first case of immune‐mediated pancytopenia in a patient treated with efalizumab. Close monitoring of all blood cell counts is warranted in light of this case.